| No | 1 | Date of announcement | 2021/06/10 | Time of announcement | 19:50:29 |
|---|---|---|---|---|---|
| Subject | Oneness Biotech and Taiwan CDE signed the agreement of regulatory science consultation and guidance on an indicator project in COVID-19 for FB704A. | ||||
| To which item it meets |
paragraph 53 | Date of events | 2021/06/10 | ||
| Statement | |||||
|
1.Date of occurrence of the event:2021/06/10
2.Company name:ONENESS BIOTECH CO., LTD. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence:FB704A, a new drug developed by Oneness Biotech has been included in the ”CDE can Help: COVID-19 Project Regulatory Science Consultation Program” by Taiwan Center for Drug Evaluation (CDE). Both parties have inked an agreement of regulatory science consultation and guidance on an indicator project in COVID-19 today. 6.Countermeasures:Oneness will consult and discuss with Taiwan CDE to accelerate the development of FB704A for treating COVID-19. 7.Any other matters that need to be specified: It takes considerable time and expenses to develop a new drug of which success can't be guaranteed. Investors shall bear such investment risk that warrants careful assessment before making investment decisions. |
|||||
